Tender Pricing at LOE: A Playbook for Winning More With Intelligent Guidance

Executive Summary

Loss of exclusivity (LOE) is becoming one of the most consequential events in the life cycle of pharmaceutical and MedTech assets. As high-revenue products move off patent and tender-based purchasing expands, commercial performance in a two to three year LOE window can determine whether an asset becomes a high-volume, margin-diluted “commodity” or a strategically managed cash generator. Recent analyses indicate that originator prices typically decline by 30–80% across high-income countries in the years following patent expiry, with some markets experiencing even steeper erosion. In publicly-funded systems where tenders dominate access, competitive pressure and payer monopsony power amplify this effect.

At the same time, the industry is facing a pronounced “patent cliff”: by 2027–2028, tens of billions in annual revenue are scheduled to lose exclusivity as flagship biologics and small molecules face generic and biosimilar competition. Many organisations still approach LOE tender pricing reactively, relying on partial market intelligence, historical discount “rules of thumb” and individual account experience. This leaves significant value at risk: margins are sacrificed unnecessarily in some markets while volumes are ceded too early in others.

The central thesis of this report is that LOE tender pricing can be transformed into a repeatable, data-driven capability built on three pillars:

Systematic analysis of historical tender awards and post-LOE price trajectories.

Using award data, public procurement portals and internal contract archives, organisations can quantify price evolution, competitor entry patterns, regional aggression levels and the relationship between price, volume commitments and award shares.

Structured pricing corridors and volume–margin trade-offs.

Instead of anchoring on a single “target discount”, leading teams define corridors between floor and ceiling prices for each asset, segment and tender type. Floors reflect fully loaded cost and minimum acceptable margin; ceilings reflect competitive reference points implied by tender awards and generic benchmarks. Within the corridor, bid choices are driven by explicit volume, share and strategic positioning objectives.

Embedded guidance and operating models for front-line teams.

Intelligence only creates value when it is translated into simple, actionable guidance at the moment of pricing. AI-enabled tender platforms and pricing engines can convert award analytics, contract terms and LOE strategy into recommended price ranges, guardrails and scenario simulations for each opportunity, while enforcing governance and documenting rationale for decisions.

Throughout the report, we describe:

• How LOE dynamics reshape price, volume and margin, and why tender environments behave differently to retail channels.
• A practical decision framework for LOE tender pricing that connects asset strategy, market archetypes and opportunity-level bid choices.
• Methods for extracting competitive intelligence from award data, including how to infer competitor aggression patterns, regional strategies and willingness to trade price for share.
• Ways to translate these insights into concrete pricing corridors, bid guidance rules and governance mechanisms that front-line teams can apply consistently.
• An implementation roadmap that starts with a focused LOE pilot portfolio and scales to a cross-asset “intelligent guidance” capability.

The intended outcome is a step change in how organisations manage value at LOE: from fragmented, locally-driven discounting to an orchestrated, insight-led approach that defends critical volumes where it matters, protects margin where it is possible and preserves strategic option value across the asset life cycle.

Table 1. Selected Late-2020s Pharma Patent Cliff Exposures (Illustrative)

By 2027–2028, a concentrated cluster of LOE events will expose well over $180 billion of branded revenue annually, with just a handful of assets already accounting for around $60 billion of that exposure.

Table 2. MedTech “Quasi-LOE” Exposure Across Mature Device Segments

In MedTech the pattern is less a single patent cliff on a hero molecule and more a rolling ‘tender cliff’ as high-value device categories mature, competitors proliferate and hospitals or payers increasingly treat products as substitutable in large framework contracts.

The LOE Pricing Challenge

LOE in commercial context

Loss of exclusivity marks the transition from protected, often premium-priced originator status into a landscape where generic or biosimilar competitors can enter with substantially lower costs and aggressive launch discounts. Multiple empirical studies have documented the price impact:

• In high-income markets, the median drug price typically falls around 40% within four years of patent expiry.
• Another multi-country analysis reports post-LOE price reductions of 30–80% over several years, depending on competitive intensity and policy frameworks.
• In some tender-driven systems, price reductions of up to 80% for generics relative to originators have been projected, particularly in off-patent segments with robust competition.

This erosion is not uniform. It varies by:

• Product type (small molecule vs biologic, chronic vs acute therapy).
• Market structure (number of competitors, tender vs free-pricing environments).
• Policy instruments (reference pricing, volume-price contracts, mandatory tenders, substitution rules).

For originator companies, LOE is therefore a portfolio-level event rather than a single binary switch. Across markets, pricing teams must decide where to prioritise revenue retention, where to protect margin and where to allow controlled erosion.

Tender-driven LOE dynamics

Tendering amplifies LOE effects. In publicly funded systems, multi-year tenders for hospitals, regional purchasing bodies or national agencies often determine the bulk of volume for off-patent molecules. Key characteristics include:

• Winner-takes-most structures. Single-winner tenders or heavily skewed multi-winner designs mean that small price differences can drive large volume shifts.
• Centralised volume commitments. Volume-price contracts combine guaranteed demand with price reductions, shifting risk toward the manufacturer.
• Formal award criteria. Non-price factors (supply security, service levels, outcomes guarantees, ESG metrics) are increasingly present, but price remains the dominant discriminant.

In this context, LOE pricing decisions have three compounding effects:

• Immediate impact on revenue and margin. Price cuts at tender may be steep but are often necessary to retain anchor positions.
• Signal effect for subsequent tenders and negotiations. Early LOE tender outcomes create reference points that competitors, payers and other regions use as benchmarks.
• Strategic positioning for the remaining life cycle. Losing key tenders early can precipitate rapid share loss, while disciplined participation in targeted tenders can preserve a profitable niche.

Why LOE tender pricing requires a distinct approach

Pre-LOE pricing is dominated by value-based arguments, differential access strategies and indication-specific evidence. Mature generic environments are often governed by commoditised discount ladders. LOE tender windows sit between these two states and require:

• Explicit scenario planning. Different competitors bring different cost bases and strategic imperatives; LOE tenders must accommodate scenarios ranging from single generic entrants to crowded bidding landscapes.
• High-quality competitive intelligence. Traditional market research is slow and high level; tender award data offers more granular and timely signals.
• Integrated view of price, volume and terms. Unit price alone is a poor proxy for value. Volume guarantees, exclusivity, supply commitments and risk-sharing mechanics meaningfully alter the economics.

Without a tailored LOE approach, organisations typically fall into one of two failure modes:

• Over-defence: aggressive uniform discounting across markets to “hold share at all costs”, destroying margin even in markets where competition is slow to materialise.
• Passive erosion: maintaining pre-LOE price logic in tender environments, leading to rapid loss of anchor awards and irreversible share declines.

Framework for LOE Tender Pricing Strategy

This section proposes a practical framework that links asset strategy to opportunity-level bid decisions. It can be implemented manually or embedded within AI-enabled tender pricing solutions.

Step 1 – Define the LOE role of the asset

For each asset, leadership should articulate a clear LOE intent by market cluster:

Volume-maximising cash generator

• Objective: maintain high volume at reduced margin to maximise cumulative cash flow.
• Typical context: high-volume chronic therapies with strong brand recognition, favourable cost of goods and robust manufacturing capacity.

Margin-protected niche

• Objective: protect price and focus on segments that value brand, continuity of supply or differentiated services.
• Typical context: complex biologics, specialised delivery forms, or markets with lower generic penetration.

Orderly exit or selective participation

• Objective: avoid value-destructive contracts and retain presence only where economics or strategic relationships justify it.

This strategic intent informs the acceptable position within pricing corridors and the willingness to trade price for share.

Step 2 – Build LOE pricing corridors

Pricing corridors set realistic bounds for bids based on economics and competition. They should be constructed for each asset, major segment and tender archetype (e.g. national, regional, hospital).

Ingredients for corridors:

• Economic floor
  • Fully loaded cost: manufacturing, logistics, lifecycle rebates, service obligations.
  • Target minimum margin: often portfolio-determined (e.g. minimum contribution margin thresholds).
• Competitive ceiling
  • Historical award prices pre- and post-LOE in the same or analogous markets.
  • Generic and biosimilar price benchmarks relative to originator (e.g. generics at 20–30% of originator price, biosimilars at roughly half, depending on market).
• Market and policy filters
  • Presence of reference pricing or mandatory discounts.
  • Volume-price or risk-sharing policies that might justify more aggressive pricing in exchange for volume security.

Figure 1. LOE Pricing Corridor (Illustrative)

Price (as % of pre-LOE list) over time since generic entry, with the shaded band representing the economic floor and competitive ceiling, and dots indicating historical tender awards.

Step 3 – Volume–margin trade-off analysis

Corridors provide bounds, but bid selection requires explicit trade-offs between price, share and margin. A simple yet powerful approach is to create scenario tables per tender:

• Scenario A – Defend anchor share
  • Price closer to corridor floor.
  • Assumes high share retention (e.g. >70%).
  • Lower unit margin, high contribution via volume.
• Scenario B – Balanced approach
  • Mid-corridor price.
  • Moderate share (e.g. 30–50%), aiming to remain a “must-carry” option without being price leader.
• Scenario C – Premium niche
  • Price closer to corridor ceiling.
  • Lower share (e.g. ≤20%), focusing on segments valuing continuity, brand or differentiated service.

For each scenario, teams should calculate:

• Expected net revenue and contribution margin.
• Impact on manufacturing capacity utilisation and supply risk.
• Signal implications for adjacent markets and future tenders (e.g. whether a deep discount will be used as reference elsewhere).

 Step 4 – Strategic positioning matrix

To align decisions across markets, organisations can use a simple matrix:

• Y-axis: market strategic importance (high to low).
• X-axis: competitive density and payer bargaining power (low to high).

Each asset–market pair is mapped into this matrix, yielding archetypes such as:

• High importance / low competition: protect price, avoid unnecessary early erosion.
• High importance / high competition: prioritise volume-maximising or balanced strategies; invest heavily in intelligence and scenario planning.
• Low importance / high competition: selective participation; avoid race-to-the-bottom tenders that fail contribution thresholds.

This matrix becomes the “front page” of LOE tender strategy, guiding corridor calibration and scenario preferences.

Competitive Intelligence from Tender Awards

Tender award data is one of the richest yet under-exploited sources of competitive intelligence for LOE pricing. Public procurement portals, tender platforms and internal archives contain detailed records of who won, at what price and under what terms.

Data sources and integration

Key inputs include:

• Public award databases (national and regional portals, TED, national procurement platforms).
• Internal contracting systems with historical tenders, submitted bids and awarded prices.
• Market intelligence providers and AI platforms that aggregate tender notices, awards, volumes and competitor participation.

The first step is to standardise and integrate this data into a consolidated tender awards dataset: products mapped to ATC or device categories, prices normalised per unit or defined daily dose, and tender types classified consistently.

Extracting competitor behaviour patterns

Once integrated, several analytical lenses can reveal behaviour that is critical for LOE decisions:

1. Pricing trajectories by competitor and region

• • Chart competitor prices as a percentage of originator list over time and across regions.
  • Identify “lead aggressors” vs “followers” and markets where entrants are unusually cautious.

2. Entry timing and bid aggressiveness at LOE

• • For key molecules, map when each generic or biosimilar first appears in tender awards and at which discount level relative to originator and existing generics.
  • Distinguish between challengers using deep initial discounts vs “step-down” strategies over multiple cycles.

3. Share-of-award and supplier concentration

• • Calculate share of awarded volume or value by supplier across tenders, identifying markets trending toward single-supplier dominance vs diversified multi-winner structures.

4. Sensitivity of award outcomes to non-price criteria

• • Compare price differences among winners and losers in tenders where technical or quality scores are published.
  • Identify segments where non-price attributes (supply history, quality, service) allow incumbents to maintain price premia.

These analyses can be operationalised into competitor “playbooks”: for example, Generic A is consistently the most aggressive early entrant in Central Europe but moderate in Nordics; Originator B typically trades price for volume only where national volume-price schemes are available.

Advanced analytics and AI

Machine learning approaches can increase predictive power by modelling the relationship between unit prices and multiple predictors: tender type, number of bidders, market, contract length, and policy environment.

Use cases include:

• Price prediction models that estimate likely winning price ranges for upcoming tenders.
• Win-probability models that simulate the chance of success at different price points within the corridor.
• Signal detection that flags when competitor behaviour deviates significantly from historical patterns, suggesting strategic shifts.

Such models are particularly valuable near LOE, when uncertainty is highest and competitors are adjusting playbooks in real time.

Translating Intelligence into Pricing Corridors and Bid Guidance

Collecting and analysing data is not sufficient; the ultimate goal is to deliver simple, trusted guidance to the teams responsible for setting tender prices.

From analytics to operational guidance

A practical structure for operationalising guidance is:

• Market-specific LOE playcards
• • Summarise for each market: LOE role of the asset, pricing corridor, competitor archetypes, key policy constraints and volumes at stake.
• Bid recommendation engines
• • For each live tender, combine corridor, competitor patterns, tender type and strategic objectives to propose a recommended price, plus upper and lower bounds.
• Decision logging and learning loops
• • Capture chosen price, rationale and outcome; feed this back into the models and playcards to refine guidance.

Example: turning award data into guidance

Consider an LOE molecule with the following insights from award analytics:

• In Region A, three generics have entered, and tender prices have converged to 25–30% of pre-LOE originator price within two tender cycles.
• In Region B, only one biosimilar is present; prices remain around 60–65% of originator levels and tenders are multi-winner.

For a national tender in Region A, the guidance might specify:

• Corridor: 20–35% of pre-LOE price.
• Strategic recommendation: adopt a volume-maximising strategy, with bids in the 22–25% range to retain anchor share.
• Mandatory governance: business case required to bid above 30%, given historical auction dynamics.

For Region B:

• Corridor: 45–70%.
• Strategic recommendation: maintain a balanced or premium niche position in the 55–65% range, emphasising non-price attributes.
• Conditions for more aggressive pricing: only if tender design shifts toward winner-takes-most or volume guarantees increase substantially.

Guardrails and governance

To avoid value-destructive decisions, organisations should institute:

• Global and regional guardrails on minimum acceptable margins and maximum discounts at LOE.
• Escalation thresholds for bids outside recommended corridors or involving large single-buyer volume concentrations.
• Governance committees that review high-impact LOE tenders, particularly in early cycles where reference points are being set.

Local Market and Contract Term Adaptation

Even with global frameworks, LOE tender pricing must be tailored to local realities.

Market archetypes

Common market archetypes include:

• Highly centralised, tender-driven systems
  • National or regional monopoly buyers, frequent single-winner tenders, strong price pressure but also large, predictable volumes.
• Hybrid systems with mixed tender and reimbursement mechanisms
  • Hospital tenders coexist with retail reimbursement; price signals from one channel influence the other.
• Fragmented, hospital-level tendering
  • Multiple hospital networks or insurers run independent tenders; competitive dynamics and price elasticity vary widely.

The LOE framework should specify differentiated discount bands, volume expectations and participation criteria for each archetype.

Role of contract terms

Contract design can materially change the economics of apparent “headline prices”:

• Volume-price contracts: deeper discounts in exchange for guaranteed or minimum volumes can be attractive if manufacturing capacity and supply reliability are strong.
• Multi-winner tenders: lower price elasticity may permit higher prices if non-price criteria and supply continuity matter more.
• Outcome- or performance-linked contracts: particularly relevant for biologics and complex therapies, where payers may accept higher prices in exchange for risk sharing.

Tender pricing guidance should therefore always be expressed as a function of both unit price and term structure (volume, duration, exclusivity, penalties).

Operating Model and Technology Enablers

Cross-functional LOE squads

Effective LOE tender pricing requires coordinated input from:

• Global and regional pricing and market access.
• Tender and contracting teams.
• Finance and business planning.
• Supply chain and manufacturing.

Establishing cross-functional LOE “squads” for priority assets ensures that strategic intent, corridor design, competitive intelligence and front-line guidance are aligned.

Data and tooling

Key enablers include:

• A centralised tender and contract data lake, aggregating public awards, internal bid histories and contract terms.
• Analytics and AI platforms capable of handling large volumes of procurement data, predicting prices and win probabilities, and surfacing competitor behaviour shifts.
• Workflow-integrated guidance tools, such as AI-driven tender pricing assistants, that plug directly into bid preparation processes and CRM systems, ensuring guidance is available at the point of decision.

Specialised platforms, including those focused on tender intelligence and pricing decision support (such as Vamstar’s AI-driven solutions for tenders and pricing), demonstrate how these capabilities can be combined to deliver near real-time guidance using award data, price histories and contract structures as inputs.

Implementation Roadmap

A pragmatic approach to building LOE tender pricing capabilities can follow four stages:

Stage 1 – Diagnostic and prioritisation

• Identify the LOE portfolio for the next 3–5 years, with revenue at risk by region.
• Map markets into archetypes and assign provisional LOE roles (cash generator, niche, selective).
• Conduct a rapid awards and price trajectory analysis for 2–3 flagship molecules to establish current state.

Stage 2 – Corridor design and pilot

• Build pricing corridors for selected asset–market combinations, using available award and contract data.
• Develop playcards and simple scenario tools for front-line teams in a subset of priority markets.
• Run a pilot across one LOE cycle or key tender season; capture decisions, rationale and outcomes.

Stage 3 – Scale and embed intelligent guidance

• Expand corridor methodology to broader LOE portfolio and additional markets.
• Integrate award analytics into standard tender pricing workflows through AI-enabled tools and dashboards.
• Formalise governance structures, guardrails and performance metrics (e.g. retained LOE revenue, margin vs plan, variance between guided and actual bids).

Stage 4 – Continuous improvement and learning

• Regularly update models and corridors as new awards, competitors and policies emerge.
• Use post-tender reviews to refine assumptions on price elasticity, competitor strategies and volume responses.
• Link LOE learnings back into earlier life-cycle phases, informing launch and mid-cycle pricing strategies.

Risk Management and Governance

LOE tender pricing is not merely a question of optimisation; mis-steps can have systemic consequences:

• Excessive price competition can undermine supply viability and contribute to drug shortages, especially in generics.
• Deep discounts in one market can leak into international reference systems, compressing prices elsewhere.
• Over-reliance on a single supplier in tenders can create supply security risks for health systems and reputational risks for manufacturers if shortages occur.

Robust governance mechanisms should therefore encompass:

• Ethical and sustainability considerations in pricing decisions, particularly in markets with limited alternative suppliers.
• Structured risk assessments for large LOE tenders, including supply, reputational and policy risks.
• Scenario planning for adverse outcomes, such as unexpectedly aggressive competitor entry or new policy instruments (e.g. volume-based procurement mandates).

Conclusion

Loss of exclusivity is no longer a predictable, linear end-of-life erosion curve. In tender-driven markets, it is an inflection point where data, analytics and disciplined strategy can materially alter the trajectory of revenue and margin. Price declines of 30–80% post-LOE are common across high-income markets, yet the timing, depth and distribution of that erosion are heavily influenced by how originators and competitors behave in the first tender cycles.

By systematically analysing tender awards, constructing robust LOE pricing corridors, and embedding intelligent guidance into front-line workflows, pharmaceutical and MedTech organisations can move from reactive discounting to proactive value management. Cross-functional LOE squads, supported by AI-enabled tender and pricing platforms, can ensure that each bid reflects not just local intuition but a global understanding of competitive dynamics, contract economics and long-term strategic objectives.

Sources:

The data in this report has been compiled from publicly available information, combined with Vamstar’s internal market insights and analysis, and the following sources:

• Merck / Keytruda sales and loss-of-exclusivity context:
  • https://www.biopharmadive.com/news/merck-keytruda-subcutaneous-cancer-sales-drug-delivery/801889/
  • https://www.pharmavoice.com/news/merck-keytruda-subcutaneous-cancer-sales-drug-delivery/761607/
• Gardasil 9 sales and US patent expiry timing:
  • https://www.reuters.com/business/healthcare-pharmaceuticals/merck-prevails-gardasil-safety-litigation-2025-03-11/
• Eliquis and Opdivo revenue and patent-expiry horizon:
  • https://www.bms.com/investor-statement-on-eliquis-revenue-under-ira.html
  • https://www.proclinical.com/blogs/2024-2/top-10-drugs-with-patents-due-to-expire-in-the-next-5-years
• Industry-wide patent cliff estimates for 2027–2028 and 2025–2030:
  • https://www.irishtimes.com/business/2025/07/11/the-looming-patent-cliff-facing-big-pharma/
  • https://trial.medpath.com/news/bdeaa1ba345678a3/pharmaceutical-industry-braces-for-236-billion-patent-cliff-by-2030-strategic-responses-from-major-players
• Global orthopaedic implants market size and outlook:
  • https://www.fortunebusinessinsights.com/industry-reports/orthopedic-implants-market-101659
  • https://www.towardshealthcare.com/insights/orthopedic-implant-market-sizing
• Drug-eluting stent market size and forecast:
  • https://www.grandviewresearch.com/horizon/outlook/drug-eluting-stent-market-size/global
  • https://www.businesswire.com/news/home/20240501698204/en/Global-Drug-Eluting-Stents-Strategic-Research-Report-2024-Market-to-Reach-11.7-Billion-by-2030—JJ-Exit-from-DES-Market-Improves-Prospects-for-Competitors—ResearchAndMarkets.com
• Transcatheter aortic valve replacement / structural heart market outlook:
  • https://www.grandviewresearch.com/industry-analysis/transcatheter-aortic-valve-replacement-tavr-market
  • https://www.mordorintelligence.com/industry-reports/transcatheter-aortic-valve-replacement-market
• EU public medical device tenders and annual contract value:
  • https://www.reuters.com/business/healthcare-pharmaceuticals/eu-bars-chinese-firms-most-medical-device-tenders-2025-06-20/